KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Invested Capital (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Invested Capital for 17 consecutive years, with $63.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 3.78% to $63.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $63.3 billion, a 3.78% decrease, with the full-year FY2025 number at $63.3 billion, down 3.78% from a year prior.
  • Invested Capital was $63.3 billion for Q4 2025 at Bristol Myers Squibb, down from $67.3 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $89.1 billion in Q2 2021 to a low of $335.0 million in Q4 2022.
  • A 5-year average of $51.0 billion and a median of $50.0 billion in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: plummeted 99.22% in 2022, then soared 11785.97% in 2023.
  • Bristol Myers Squibb's Invested Capital stood at $43.1 billion in 2021, then plummeted by 99.22% to $335.0 million in 2022, then skyrocketed by 11785.97% to $39.8 billion in 2023, then soared by 65.3% to $65.8 billion in 2024, then fell by 3.78% to $63.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Invested Capital are $63.3 billion (Q4 2025), $67.3 billion (Q3 2025), and $49.2 billion (Q2 2025).